The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

In severe hypokalemia not responding to maximal doses of potassium supplementation, a decrease in insulin infusion may be considered. Transition to subcutaneous insulin is recommended when ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes: Maryland Monday, February 17, 202 ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...

insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg ...

As a rapid-acting human insulin, Merilog helps to lower mealtime ... including hypoglycemia (low blood sugar), severe allergic reactions and hypokalemia (low potassium in blood).